CONGRESS|#EHA2021| Wang Di, presented data on BCMA-targeting CAR construct (CT103A), safety & efficacy. CT103A is safe, highly productive with long persistent in RRMM patients #mmsm #myeloma, Huazhong University of Science & Technology, Wuhan pic.twitter.com/yZHEuoPKUs
— Multiple Myeloma Hub (@MM_Hub) June 11, 2021